AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

AbbVie (ABBV) said on Monday that its late-stage trial evaluating its drug Venetoclax in combination with Azacitidine in the ...

AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...

AbbVie (ABBV) stock in focus after a Phase 3 trial setback for leukemia therapy venetoclax marketed with Roche (RHHBY) in ...

The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...

Roche and AbbVie have come up short again in their effort to gain an additional indication for their blockbuster blood cancer ...

If approved, Zemcelpro® is expected to:increase access to donor-derived stem cell transplantation, which offers a potentially curative option for haematologic malignancies, including leukemias and mye ...

AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) ...

All of us produce a growth factor – called IL-15 – which effectively protects us from cancers. It's role is to boost the ...